Boost for medical research institutes
Print Edition
The first drug manufacturing license for medical research institutes in China was issued by Shanghai authorities yesterday, lifting the restrictions imposed on such drug research organizations from participating in medicine bidding and procurement.
Some provinces require drug research institutes to obtain the license before they are allowed to participate in bidding and procurement, leaving them unable to enjoy some preferential policies, the Shanghai Drug Administration said.
The first license was issued to Anbison Lab.
鈥淭he reform will stimulate the innovation vitality of biomedicine companies,鈥 said Zhang Qing, deputy director of the administration.
Applications for drug manufacturing license from nine drug research institutes in Shanghai are being reviewed, according to the administration.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
